S. Hoshide

Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody, against Shiga-Like Toxin 2 in Healthy Adults and in Pediatric Patients Infected with Shiga-Like Toxin-Producing <i>Escherichia coli</i>

Eduardo López, María M Contrini, Eduardo Glatstein et al. · Antimicrobial Agents and Chemotherapy · 2009 · 103 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +11

<b><i>In vitro</i></b>drug–drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition

M. Mukoyoshi, Shinichi Nishimura, S. Hoshide et al. · Xenobiotica · 2008 · 58 citations

Medicine, Pharmacokinetics, Pharmacology +17

PK/PD and Safety of a Single Dose of TMX‐67 (Febuxostat) in Subjects with Mild and Moderate Renal Impairment

S. Hoshide, Yoshimasa Takahashi, Takuro Ishikawa et al. · Nucleosides Nucleotides & Nucleic Acids · 2004 · 57 citations

Medicine, Pharmacokinetics, Pharmacology +15

An Epidemiologic Surveillance of Shiga-like Toxin-producing Escherichia coli Infection in Argentinean Children

Eduardo López, María M Contrini, Eduardo Glatstein et al. · The Pediatric Infectious Disease Journal · 2011 · 50 citations

Life Sciences, Infectious Diseases, Pediatrics +17

Pharmacokinetics and Pharmacodynamics of Febuxostat (TMX‐67), a Non‐Purine Selective Inhibitor of Xanthine Oxidase/Xanthine Dehydrogenase (NPSIXO) in Patients with Gout and/or Hyperuricemia

Keiji Komoriya, S. Hoshide, Kenji Takeda et al. · Nucleosides Nucleotides & Nucleic Acids · 2004 · 40 citations

Medicine, Pharmacokinetics, Pharmacology +9